ArticleFrontiers in microbiology2026
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deoxynivalenol-induced cellular signal transduction: research progress on toxicological effects, molecular mechanisms, and biological intervention strategies.Molecular biology reports · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Deoxynivalenol (DON), a prevalent mycotoxin in grains and feed, poses a serious threat to animal health by inducing intestinal dysfunction. While some probiotics are known to mitigate DON toxicity, the multifaceted protective effects of Methods: Investigations were conducted Results: The MY-1 supernatant restored IPEC-J2 cell viability and ameliorated DON-induced ultrastructural damage. MY-1 alleviated oxidative stress by reducing MDA and enhancing T-AOC, while inhibiting pro-inflammatory cytokines (TNF-α, IL-1α) and promoting the anti-inflammatory cytokine IL-4. In mice, MY-1 mitigated DON-induced growth inhibition and intestinal pathological damage, restored tight junction protein expression, and regulated apoptosis-related genes. Gut microbiota analysis showed that MY-1 reversed DON-induced dysbiosis, restoring alpha diversity and beta diversity structure, and modulated the abundances of dominant genera such as Discussion: This study demonstrates that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.